Skip to main content
Top
Published in: Journal of Inflammation 1/2013

Open Access 01-12-2013 | Research

Effect of Serenoa repens (Permixon®) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma

Authors: Ida Silvestri, Susanna Cattarino, AnnaMaria Aglianò, Chiara Nicolazzo, Susanna Scarpa, Stefano Salciccia, Luigi Frati, Vincenzo Gentile, Alessandro Sciarra

Published in: Journal of Inflammation | Issue 1/2013

Login to get access

Abstract

Background

To analyze the expression at basal level of inflammation-related cytokines and chemokines and the activation status of the NF-κB pathway, together with the proliferation and apoptosis indexes in two widely used in vitro tumor models, the androgen-dependent human Prostate Cancer (PC) cell line LNCaP and the androgen-independent PC3 , and in primary cultures of human PC cells. To assess in these models and primary cultures, the effects of Serenoa repens (LSESr, Permixon®) on proliferation/apoptosis ratio, inflammation-related genes expression and NF-κB pathway activation.

Methods

The expression of IL-6, CCL-5, CCL-2, COX-1, COX-2, iNOS inflammation-related genes has been evaluated at the mRNA level in two in vitro human PC models (LNCaP and PC3 cell lines) and in 40 independent human prostatic primary cultures obtained from PC patients undergoing radical prostatectomy. Tissue fragments were collected from both PC lesions and normal hyperplastic tissue counterparts for each case. All cultures were treated with two different amounts of Permixon® (44 and 88 μg/ml) for different time points (16, 24, 48 and 72 hours), depending on the cell type and the assay; the expression of inflammation-related genes, cell growth (proliferation/apoptosis ratio) and NF-κB activation has been analyzed in treated and untreated cells by means of semi-quantitative RNA-PCR, cell proliferation and immunofluorescence respectively.

Results

We detected a significant reduction (p <0.001) in PC and normal cells proliferation due to Permixon ® treatment. This result was related to an increase of the apoptotic activity showed by an increase in the number of anti-caspase-3 fluorescent cells. Almost all the inflammation-related genes (IL-6, CCL-5, CCL-2, COX-2 and iNOS) were expressed at the basal level in in vitro cultured cells and primary cultures and down-regulated by Permixon® treatment. This treatment interfered with NF-kB activation, detecting by the translocation of more than 30% of NF-κB p65 subunit to the nucleus.

Conclusions

The present study confirms the expression of inflammatory pattern in PC. We showed the effect of Permixon® on down-regulation of inflammatory-related genes in cell lines and in primary cultures. The inhibitory effect of Permixon® on cell growth could be partly associated to the down-regulation of inflammatory-related genes and to the activation of NF-κB pathway in prostate tissue.
Appendix
Available only for authorised users
Literature
1.
go back to reference Alcaraz A, Hammerer P, Tubaro A, Schroder FH, Castro R: Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol. 2009, 55: 864-875. 10.1016/j.eururo.2008.11.011.PubMedCrossRef Alcaraz A, Hammerer P, Tubaro A, Schroder FH, Castro R: Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol. 2009, 55: 864-875. 10.1016/j.eururo.2008.11.011.PubMedCrossRef
2.
go back to reference Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, Gentile V: Inflammation and chronic prostatic diseases: evidence for a link?. Eur Urol. 2007, 52: 964-972. 10.1016/j.eururo.2007.06.038.PubMedCrossRef Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, Gentile V: Inflammation and chronic prostatic diseases: evidence for a link?. Eur Urol. 2007, 52: 964-972. 10.1016/j.eururo.2007.06.038.PubMedCrossRef
4.
go back to reference De Nunzio C, Kramer G, Marberger M: The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011, 60 (1): 106-117. 10.1016/j.eururo.2011.03.055.PubMedCrossRef De Nunzio C, Kramer G, Marberger M: The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011, 60 (1): 106-117. 10.1016/j.eururo.2011.03.055.PubMedCrossRef
5.
go back to reference Caruso C, Balistreri CR, Candore G: Polymorphisms of pro- inflammatory genes and prostate cancer risk: a pharmacogenomic approach. Cancer Immunol Immunother. 2009, 58: 1919-1933. 10.1007/s00262-009-0658-y.PubMedCrossRef Caruso C, Balistreri CR, Candore G: Polymorphisms of pro- inflammatory genes and prostate cancer risk: a pharmacogenomic approach. Cancer Immunol Immunother. 2009, 58: 1919-1933. 10.1007/s00262-009-0658-y.PubMedCrossRef
6.
go back to reference Klein EA, Silverman R: Inflammation, infection, and prostate cancer. Curr Opin Urol. 2008, 18: 315-319. 10.1097/MOU.0b013e3282f9b3b7.PubMedCrossRef Klein EA, Silverman R: Inflammation, infection, and prostate cancer. Curr Opin Urol. 2008, 18: 315-319. 10.1097/MOU.0b013e3282f9b3b7.PubMedCrossRef
7.
go back to reference Chung LW, Baseman A, Assikis V, Zhau HE: Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol. 2005, 173 (1): 10-20. 10.1097/01.ju.0000141582.15218.10.PubMedCrossRef Chung LW, Baseman A, Assikis V, Zhau HE: Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol. 2005, 173 (1): 10-20. 10.1097/01.ju.0000141582.15218.10.PubMedCrossRef
8.
go back to reference Carilla E, Briley M, Fauran F, Sultan C, Duvilliers C: Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem. 1984, 20 (1): 521-523. 10.1016/0022-4731(84)90265-6.PubMedCrossRef Carilla E, Briley M, Fauran F, Sultan C, Duvilliers C: Binding of Permixon, a new treatment for prostatic benign hyperplasia, to the cytosolic androgen receptor in the rat prostate. J Steroid Biochem. 1984, 20 (1): 521-523. 10.1016/0022-4731(84)90265-6.PubMedCrossRef
9.
go back to reference Ragab A, Ragab-Thomas JMF, Delhan A: Effects of Permixon (Sereprostat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. International workshop in Urology. New trends in bladder cancer chemotherapy—new trends in BPH etiopathogenesis. Edited by: Di Silverio F, Steg A. 1998, Acta Medica, 293-296. Ragab A, Ragab-Thomas JMF, Delhan A: Effects of Permixon (Sereprostat in Spain) on phospholipase A2, activity and on arachidonic acid metabolism in cultured prostatic cells. International workshop in Urology. New trends in bladder cancer chemotherapy—new trends in BPH etiopathogenesis. Edited by: Di Silverio F, Steg A. 1998, Acta Medica, 293-296.
10.
go back to reference Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, López FA: BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003, 44 (5): 549-555. 10.1016/S0302-2838(03)00368-3.PubMedCrossRef Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, López FA: BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003, 44 (5): 549-555. 10.1016/S0302-2838(03)00368-3.PubMedCrossRef
11.
go back to reference Di Silverio F, D'Eramo G, Lubrano C: Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign 2003 prostatic hypertrophy patients. Eur Urol. 1992, 21 (4): 309-314.PubMed Di Silverio F, D'Eramo G, Lubrano C: Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign 2003 prostatic hypertrophy patients. Eur Urol. 1992, 21 (4): 309-314.PubMed
12.
go back to reference Paubert-Braquet M, Mencia Huerta JM, Cousse H, Braquet P: Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997, 57 (3): 299-304. 10.1016/S0952-3278(97)90548-2.PubMedCrossRef Paubert-Braquet M, Mencia Huerta JM, Cousse H, Braquet P: Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostaglandins Leukot Essent Fatty Acids. 1997, 57 (3): 299-304. 10.1016/S0952-3278(97)90548-2.PubMedCrossRef
13.
go back to reference Vacherot F, Azzouz M, Gil-Diez-De-Medina S: Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia. Prostate. 2000, 45 (3): 259-266. 10.1002/1097-0045(20001101)45:3<259::AID-PROS9>3.0.CO;2-G.PubMedCrossRef Vacherot F, Azzouz M, Gil-Diez-De-Medina S: Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia. Prostate. 2000, 45 (3): 259-266. 10.1002/1097-0045(20001101)45:3<259::AID-PROS9>3.0.CO;2-G.PubMedCrossRef
14.
go back to reference Peehl DM: Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer. 2005, 12 (1): 19-47. 10.1677/erc.1.00795.PubMedCrossRef Peehl DM: Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer. 2005, 12 (1): 19-47. 10.1677/erc.1.00795.PubMedCrossRef
15.
go back to reference Peehl DM: Are primary cultures realistic models of prostate cancer?. J Cell Biochem. 2004, 91 (1): 185-195. 10.1002/jcb.10691.PubMedCrossRef Peehl DM: Are primary cultures realistic models of prostate cancer?. J Cell Biochem. 2004, 91 (1): 185-195. 10.1002/jcb.10691.PubMedCrossRef
16.
go back to reference Paubert-Braquet M, Cousse H, Raynaud JP, Mencia-Huerta JM, Braquet P: Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol. 1998, 33 (3): 340-347. 10.1159/000019570.PubMedCrossRef Paubert-Braquet M, Cousse H, Raynaud JP, Mencia-Huerta JM, Braquet P: Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol. 1998, 33 (3): 340-347. 10.1159/000019570.PubMedCrossRef
17.
go back to reference Petrangeli E, Lenti L, Buchetti B: Lipido-sterolic extract of Serenoa repens (LSESr, Permixon) treatment affects human prostate cancer cell membrane organization. J Cell Physiol. 2009, 219 (1): 69-76. 10.1002/jcp.21648.PubMedCrossRef Petrangeli E, Lenti L, Buchetti B: Lipido-sterolic extract of Serenoa repens (LSESr, Permixon) treatment affects human prostate cancer cell membrane organization. J Cell Physiol. 2009, 219 (1): 69-76. 10.1002/jcp.21648.PubMedCrossRef
18.
go back to reference Bayne CW, Ross M, Donnelly F, Habib FK: The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. J Urol. 2000, 164: 876-881. 10.1016/S0022-5347(05)67330-2.PubMedCrossRef Bayne CW, Ross M, Donnelly F, Habib FK: The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. J Urol. 2000, 164: 876-881. 10.1016/S0022-5347(05)67330-2.PubMedCrossRef
19.
go back to reference Ravenna L, Di Silverio F, Russo MA: Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines. Prostate. 1996, 29 (4): 219-230. 10.1002/(SICI)1097-0045(199610)29:4<219::AID-PROS3>3.0.CO;2-6.PubMedCrossRef Ravenna L, Di Silverio F, Russo MA: Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines. Prostate. 1996, 29 (4): 219-230. 10.1002/(SICI)1097-0045(199610)29:4<219::AID-PROS3>3.0.CO;2-6.PubMedCrossRef
20.
go back to reference Bayne CW, Donnelly F, Ross M, Habib FK: Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate. 1999, 40 (4): 232-241. 10.1002/(SICI)1097-0045(19990901)40:4<232::AID-PROS4>3.0.CO;2-0.PubMedCrossRef Bayne CW, Donnelly F, Ross M, Habib FK: Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate. 1999, 40 (4): 232-241. 10.1002/(SICI)1097-0045(19990901)40:4<232::AID-PROS4>3.0.CO;2-0.PubMedCrossRef
22.
go back to reference Green DR: Apoptotic pathways: paper wraps stone blunts scissors. Cell. 2000, 102 (1): 1-4. 10.1016/S0092-8674(00)00003-9.PubMedCrossRef Green DR: Apoptotic pathways: paper wraps stone blunts scissors. Cell. 2000, 102 (1): 1-4. 10.1016/S0092-8674(00)00003-9.PubMedCrossRef
23.
go back to reference Yang Y, Ikezoe T, Zheng Z, Hirokuni T, Koeffler HP, Zhu WG: Saw Palmetto induced growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling. Int J Oncol. 2007, 31: 593-600.PubMed Yang Y, Ikezoe T, Zheng Z, Hirokuni T, Koeffler HP, Zhu WG: Saw Palmetto induced growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling. Int J Oncol. 2007, 31: 593-600.PubMed
24.
go back to reference Hill B, Kyprianou N: Effect of Permixon on human prostate cell growth: lack of apoptotic action. Prostate. 2004, 61: 73-80. 10.1002/pros.20088.PubMedCrossRef Hill B, Kyprianou N: Effect of Permixon on human prostate cell growth: lack of apoptotic action. Prostate. 2004, 61: 73-80. 10.1002/pros.20088.PubMedCrossRef
25.
go back to reference Aglianò AM, Santangelo C, Silvestri I, Gazzaniga P, Giuliani L, Naso G, Frati L, Castiglia R: On chromosomal instability: what is the karyotype of your 32D CI3 cell line. Blood. 2000, 95 (11): 3636-3637.PubMed Aglianò AM, Santangelo C, Silvestri I, Gazzaniga P, Giuliani L, Naso G, Frati L, Castiglia R: On chromosomal instability: what is the karyotype of your 32D CI3 cell line. Blood. 2000, 95 (11): 3636-3637.PubMed
26.
go back to reference Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC: Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res. 2003, 9 (1): 370-376.PubMed Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC: Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res. 2003, 9 (1): 370-376.PubMed
27.
go back to reference Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441 (7092): 431-436. 10.1038/nature04870.PubMedCrossRef Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441 (7092): 431-436. 10.1038/nature04870.PubMedCrossRef
28.
go back to reference Huang CH, Guh JH, Chen GS, Lu PH, Chern JW: Anticancer activity of a cyclooxygenase inhibitor, CX9051, in human prostate cancer cells: the roles of NF-κB and crosstalk between the extrinsic and intrinsic apoptoticpathways. Naunyn-Schmied-Arch Pharmacol. 2010, 382: 159-169. 10.1007/s00210-010-0528-3.CrossRef Huang CH, Guh JH, Chen GS, Lu PH, Chern JW: Anticancer activity of a cyclooxygenase inhibitor, CX9051, in human prostate cancer cells: the roles of NF-κB and crosstalk between the extrinsic and intrinsic apoptoticpathways. Naunyn-Schmied-Arch Pharmacol. 2010, 382: 159-169. 10.1007/s00210-010-0528-3.CrossRef
29.
go back to reference Fan C, Yang J, Engelhardt JF: Temporal pattern of NFkappaB activation influences apoptotic cell fate in a stimuli-dependent fashion. J Cell Sci. 2002, 115: 4843-4853. 10.1242/jcs.00151.PubMedCrossRef Fan C, Yang J, Engelhardt JF: Temporal pattern of NFkappaB activation influences apoptotic cell fate in a stimuli-dependent fashion. J Cell Sci. 2002, 115: 4843-4853. 10.1242/jcs.00151.PubMedCrossRef
30.
go back to reference Loveridge CJ, MacDonald ADH, Thoms HC, Dunlop MG, Stark LA: The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kB. Oncogene. 2008, 27: 2648-2655. 10.1038/sj.onc.1210891.PubMedCrossRef Loveridge CJ, MacDonald ADH, Thoms HC, Dunlop MG, Stark LA: The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-kB. Oncogene. 2008, 27: 2648-2655. 10.1038/sj.onc.1210891.PubMedCrossRef
31.
go back to reference Brady RR, Loveridge C, Dunlop MG, Stark LA: c-Src dependency of NSAID-induced effects on NF{kappa}B-mediated apoptosis in colorectal cancer cells. Carcinogenesis. 2011, 32 (7): 1069-1077. 10.1093/carcin/bgr077.PubMedCrossRef Brady RR, Loveridge C, Dunlop MG, Stark LA: c-Src dependency of NSAID-induced effects on NF{kappa}B-mediated apoptosis in colorectal cancer cells. Carcinogenesis. 2011, 32 (7): 1069-1077. 10.1093/carcin/bgr077.PubMedCrossRef
32.
go back to reference Gradilone A, Silvestri I, Scarpa S, Morrone S, Ganidni O, Pulcinelli FM, Gianni W, Frati L, Aglianò AM, Gazzanica P: Failure of apoptosis and activation on NFkappaB by colecoxib and aspirin in lung cancer cell lines. Oncol Rep. 2007, 17 (4): 823-828.PubMed Gradilone A, Silvestri I, Scarpa S, Morrone S, Ganidni O, Pulcinelli FM, Gianni W, Frati L, Aglianò AM, Gazzanica P: Failure of apoptosis and activation on NFkappaB by colecoxib and aspirin in lung cancer cell lines. Oncol Rep. 2007, 17 (4): 823-828.PubMed
33.
go back to reference Gazzaniga P, Silvestri I, Gradiolne A, Scarpa S, Morrone S, Gandini O, Gianni W, Frati L, Aglianò AM: Gemcitabine-induced apoptosis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer. Anticancer Drugs. 2007, 18 (2): 179-185. 10.1097/CAD.0b013e328010ef47.PubMedCrossRef Gazzaniga P, Silvestri I, Gradiolne A, Scarpa S, Morrone S, Gandini O, Gianni W, Frati L, Aglianò AM: Gemcitabine-induced apoptosis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer. Anticancer Drugs. 2007, 18 (2): 179-185. 10.1097/CAD.0b013e328010ef47.PubMedCrossRef
Metadata
Title
Effect of Serenoa repens (Permixon®) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinoma
Authors
Ida Silvestri
Susanna Cattarino
AnnaMaria Aglianò
Chiara Nicolazzo
Susanna Scarpa
Stefano Salciccia
Luigi Frati
Vincenzo Gentile
Alessandro Sciarra
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2013
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/1476-9255-10-11

Other articles of this Issue 1/2013

Journal of Inflammation 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.